Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

BACKGROUND: In a Phase III trial, 485 patients (≥65 years) with newly diagnosed acute myeloid leukemia received decitabine 20 mg/m(2) intravenously for 5 days every 4 weeks or a treatment choice (supportive care or cytarabine 20 mg/m(2) subcutaneously for 10 days every 4 weeks). MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Arthur, Christopher, Cermak, Jaroslav, Delaunay, Jacques, Mayer, Jiří, Mazur, Grzegorz, Thomas, Xavier, Wierzbowska, Agnieszka, Jones, Mark M, Berrak, Erhan, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295530/
https://www.ncbi.nlm.nih.gov/pubmed/25678833
http://dx.doi.org/10.2147/JBM.S64067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295530/
https://www.ncbi.nlm.nih.gov/pubmed/25678833
http://dx.doi.org/10.2147/JBM.S64067

Ejemplares similares